SCHEMBL21481097

SCHEMBL21481097

CCCCCC(CC(O)NO)C(=O)NC(C(=O)N1CCCC1CO)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC2 Q13490 1/20 0.39
DPP4 P27487 2/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
POLB P06746 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
GALR3 O60755 1/20 0.34
XIAP P98170 1/20 0.34
MLX Q9UH92 1/20 0.34
MMP1 P03956 2/20 0.33
MMP3 P08254 2/20 0.33
MMP9 P14780 2/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Actinonin SCHEMBL14490676 0.85 BIRC2 (0.56) BIRC2MMP1MMP3MMP9
Actinonin SCHEMBL279122 0.85 BIRC2 (0.56) BIRC2MMP1MMP3MMP9
Actinonin SCHEMBL12601775 0.85 BIRC2 (0.56) BIRC2MMP1MMP3MMP9
Actinonin SCHEMBL123273 0.85 BIRC2 (0.56) BIRC2MMP1MMP3MMP9
Actinonin SCHEMBL279450 0.85 BIRC2 (0.56) BIRC2MMP1MMP3MMP9
SCHEMBL21387112 0.84 BIRC2 (0.47) BIRC2DPP4DPP8DPP9POLB
SCHEMBL6294118 0.83 BIRC2 (0.55) BIRC2MMP1MMP3MMP9
SCHEMBL9495973 0.82 BIRC2 (0.44) BIRC2DPP4DPP8DPP9POLB
SCHEMBL25432158 0.81
SCHEMBL20817089 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11052154-B2 Ras protein degradation inducing molecule and pharmaceutical composition TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2021-07-06 US disclosed
US-11007269-B2 P53 degradation inducing molecule and pharmaceutical composition TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2021-05-18 US disclosed
US-20190314508-A1 P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314508-A1 P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION TP53, TP53BP1, MDM2 BIRC2 347/4885DPP4 2495/4885DPP8 1820/4885
US-11052154-B2 Ras protein degradation inducing molecule and pharmaceutical composition KRAS, G3BP1, NRAS BIRC2 166/4885DPP4 3236/4885DPP8 2398/4885
US-11007269-B2 P53 degradation inducing molecule and pharmaceutical composition TP53, TP53BP1, MDM2 BIRC2 347/4885DPP4 2495/4885DPP8 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.